SABCS^® 2019 Press Releases:

Wednesday, December 11, 2019
7:00-7:45 a.m. CT

SABCS Co-director Carlos Arteaga, MD, director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, will moderate a press conference featuring the following research. Abstracts are appended to the bottom of each news release:

• New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pretreated with T-DM1
• Updated APHINITY Trial Data Show Addition of Pertuzumab to Trastuzumab Plus Chemotherapy Continues to Yield Clinical Benefit in Patients With Operable HER2-positive Early Breast Cancer
• Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer

Wednesday, December 11, 2019
8:45 a.m. CT

• Adding Tucatinib to Trastuzumab and Chemotherapy Improves Survival for Patients with Metastatic HER2-Positive Breast Cancer

Wednesday, December 11, 2019
3:15 p.m. CT

• Combining Endocrine Therapy with a CDK4/6 Inhibitor Results In Similar Response Rates to Chemotherapy for High-Risk Luminal B Breast Cancer

Thursday, December 12, 2019
7:30-8:30 a.m. CT

SABCS Co-director C. Kent Osborne, MD, director of the Dan L Duncan Cancer Center at Baylor College of Medicine, will moderate a press conference featuring the following research. Abstracts are appended to the bottom of each news release:

• Neoadjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer with Lymph Node Involvement
• Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer
• Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment
• Partial Breast Irradiation May be as Effective as Whole Breast Irradiation in Preventing Recurrence in Patients with Early Breast Cancer

Thursday, December 12, 2019
3:15 p.m. CT

• MINDACT Trial Data Reveal Certain Women With Luminal Breast Cancer May Be Undertreated With Tamoxifen Alone

Friday, December 13, 2019
7:30-8:30 a.m. CT

SABCS Co-director Virginia Kaklamani, MD, leader of the Breast Cancer Program at UT Health San Antonio, will moderate a press conference featuring the following research. Abstracts are appended to the bottom of each news release:

• Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women
• Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type
• Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple Negative Breast Cancer
• Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial

---

 

SABCS^® 2018 Press Releases:

Wednesday, December 5, 2018
7:15-7:45 a.m. CT

SABCS Co-director Carlos Arteaga, MD, director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, will moderate a press conference featuring the following research:

• Phase III KATHERINE Clinical Trial Crossed Early Reporting Boundary and Met its Primary Endpoint
• Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer

Wednesday, December 5, 2018
12:15-12:45 p.m. CT

Dr. Arteaga will moderate a second press conference featuring the following research:

• Adjuvant Chemotherapy Might Not Add Benefit in Breast Cancer Patients who Have Excellent Response to Neoadjuvant Chemotherapy
• Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer

Thursday, December 6, 2018
7:30-8:30 a.m. CT

SABCS Co-director Virginia Kaklamani, MD, leader of the Breast Cancer Program at UT Health San Antonio, will moderate a press conference featuring the following research:

• Low-Dose Tamoxifen Was Safe and Effective at Reducing Recurrence and New Breast Disease for Patients With DCIS, LCIS, and ADH
• Circulating Tumor Cell Count Could Help Choose Treatment for Metastatic Breast Cancer Patients*
• Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer
• Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Friday, December 7, 2018
7:30-8:30 a.m. CT

SABCS Co-director C. Kent Osborne, MD, director of the Dan L Duncan Cancer Center at Baylor College of Medicine, will moderate a press conference featuring the following research:

• Exercise Performed During Adjuvant Breast Cancer Treatment May Improve Cardiovascular Function
• Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates
• Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors
• Choice of Surgery May Affect Quality of Life for Young Breast Cancer Survivors

Other Press Releases:

The following press releases on noteworthy research being presented at the symposium:

• Liquid Biopsies in SOLAR-1 Trial Predict Benefit of Alpelisib in PIK3CA-Mutant Breast Cancer
• Black Women Have Worse Breast Cancer Outcomes Despite Receiving Similar Treatment as White Women

---

 

SABCS^® 2017 Press Releases:

---

 

SABCS^® 2019 Press Releases:

Wednesday, December 11, 2019
7:00 a.m. CT

Thursday, December 12, 2019
7:30 a.m. CT

Friday, December 13, 2019
7:30 a.m. CT

---